MjLink Cannabis Business News and Press

On April 22, 2026, Acting Attorney General Todd Blanche signed an order placing state-licensed medical marijuana into Schedule III of the Controlled Substances Act. The cannabis industry declared it a turning point. In certain respects, it is.

But turning points are not endpoints. And for California cannabis retailers who operate in the most complex, most taxed, and most litigated cannabis market in the country, the April 22 order resolves far less than the headlines suggest.

The §280E Problem, Revisited

Section 280E was enacted in 1982 in response to a tax court decision that allowed a convicted drug trafficker to deduct ordinary business expenses. Congress’s response was blunt: no deduction or credit shall be allowed for any amount paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances prohibited by federal or state law. Only the cost of goods sold (or “cogs”, which is treated as an adjustment to gross income rather than a deduction) survives.

The practical consequence is financial absurdity. Cannabis businesses are taxed not on net income but on a fictional gross margin that bears little relationship to actual profitability. Effective tax rates routinely exceed 70% of gross revenue and, in loss years, can exceed 100% of cash flow. The tax obligation exists regardless of whether the business is solvent. The statute thus becomes a primary driver of insolvency, causing businesses to appear profitable for tax purposes at the precise moment they are failing.

For much of the cannabinoid supply market, the model has been simple: make the molecule, test the batch, sell the material.

If the product meets basic specifications, passes third-party testing, and can be produced at a competitive price, it is considered ready for market. That model has supported much of the consumer cannabinoid industry, where buyers often evaluate supply through potency, purity, availability, pricing, and a certificate of analysis.

Healthcare requires a different standard.

As cannabinoids begin moving into more serious functional, medical, and healthcare-oriented channels, the question becomes larger than whether a cannabinoid can be produced and sold. The question becomes whether that cannabinoid can support a defined clinical or functional application.

That is the shift now beginning to matter: from supplying cannabinoid material to developing cannabinoid ingredients.

Over the last several years, we have spent a lot of time studying how cannabis retailers make purchasing decisions.

Not just which products they buy, or how much they buy, but the entire sequence of events that begins once a buyer decides inventory needs to be ordered.

That sequence matters more than most operators realize.

In cannabis retail, inventory problems usually get diagnosed after the fact. A store has too much aging product. Cash is tied up in categories that are not moving. A vendor invoice arrives that does not match expectations. A buyer realizes a product was reordered twice. A store team receives items that were never supposed to be accepted.

By the time these issues become visible, the inventory is already in the building.

For years, cannabis operators have accepted labeling inefficiencies as an unavoidable cost of doing business. Yet, many facilities still rely on fragmented, manual workflows that require employees to export spreadsheets, copy cannabinoid results, and rekey intricate terpene data into static label templates. This traditional approach actively drains productivity, inflates labor costs, and introduces unnecessary opportunities for human error. Fortunately, a new generation of labeling technology is changing that reality.

To solve this dilemma, the cannabis industry has long desired a more integrated, streamlined approach. By connecting directly to Metrc, a modernized labeling platform effectively eliminates the manual data entry that has traditionally stalled supply chains. Instead of rebuilding templates for every batch, users can now access real-time package information straight from the source of truth to auto-populate compliant labels. This is precisely where genuine workflow innovation delivers measurable bottom-line value.

Designed specifically to erase this administrative burden, the QRlogix Software’s Metrc integration offers ready-to-print, state-specific label templates that are fully mapped to Metrc data fields. Because 100% of the Metrc data is automatically available within the system, the need for manual data entry is eliminated. Rather than typing out cannabinoid values, terpene profiles, or harvest information, users simply select the specific Metrc package they intend to print. The software handles the rest, transforming a once-tedious facility bottleneck into a remarkably simple workflow: Click. Click. Print!

This automation proves especially critical for multi-state operators navigating the fractured landscape of regional compliance. Different jurisdictions mandate wildly different warnings, layouts, and tracking metrics. Preconfigured, state-specific templates solve this challenge by providing compliant, ready-to-use designs out of the box. Because these templates map directly to Metrc data, operators can launch printing operations immediately without extensive IT development, ensuring total consistency across multiple facilities.

Ultimately, the most profound impact of this digital transformation is labor efficiency that scales alongside growth. When a facility eliminates spreadsheet exports and repetitive verification loops, tasks that previously required tens of minutes are reduced to mere seconds. As commercial cannabis operations face intensifying pricing pressures and margin compression, maximizing workflow efficiency is no longer optional. By automating data population directly from Metrc, operators can decisively eliminate human error, secure compliance, and reclaim hundreds of valuable labor hours. In an industry where efficiency dictates survival, cannabis labeling can finally be as simple as it should be when partnered with QRlogix – Click. Click. Print!

Every conversation about cannabis risk follows the same script: Regulatory uncertainty, 280E, capital access, and maybe interstate commerce, depending on the room. None of that is wrong, and operators dealing with those pressures daily don’t need me to tell them they’re real.

But after more than a decade working inside this industry, watching companies scale, stumble, and sometimes collapse, I’ve come to believe the industry is looking in the wrong direction. The risks getting the most airtime are not the ones most likely to take a healthy cannabis company down. The risk that actually keeps me up at night is quieter, and it’s been there the whole time.

It lives on the floor of your dispensary, in your cultivation facility at shift change, and at the moment a new hire decides to skip a step because no one told them why it mattered. The cannabis industry has built compliance programs. It has not built compliance cultures. And that gap is about to get a lot more expensive.

 The Policy Problem

Over the past several years, cannabis operators have invested heavily in what looks like compliance: SOPs, legal counsel, documentation frameworks, and licensing strategy. Those investments made sense. In the early days, getting and keeping a license was the whole game.

But here’s what I’ve watched happen over and over: a company builds out a solid policy framework, puts it in a binder, and then hires thirty people in ninety days to open a new market. The training program becomes whatever the most experienced employee on shift decides to show the new person. Two locations run the same process differently, and somewhere between the SOP binder and the actual shift, the gap opened up without anyone noticing. The person carrying out the policy matters as much as the policy itself, sometimes more.

The Hemp Beverage Expo (HBE) heads into its second show this June in Austin, Texas, and the energy is full speed ahead — even with November 12th looming over the industry.

With policy updates shifting rapidly and operators scrambling to brainstorm contingency plans, getting in the room with businesses and advocates from across the beverage sector has never felt more urgent. The November 12th deadline is a genuine threat to the industry’s survival, and the show is positioning itself as the place where the people fighting for this category can share knowledge, compare notes, and figure out their next moves together.

Leaders from the Hemp Beverage Alliance, Coalition for Adult Beverage Alternatives, Beverage Wholesalers for Responsible Regulation, and Wine and Spirits Wholesalers of America will all take the stage in Austin to discuss their latest efforts to shape policy and educate lawmakers.

The Data Is Building

Now that hemp beverages have been on the market for a few years and revenue is growing year over year, major enterprise market research firms are starting to dedicate real resources to tracking the sector. According to NielsenIQ’s April 2026 report “Buzz Worthy: The High Rise of THC Beverages,” THC drinks generated $239 million in sales over the past 52 weeks — a striking 135% year-over-year increase.

LeafLink’s Wholesale Cannabis Pricing Guide, drawing on over 400,000 SKUs and billions of dollars in transaction data across 18 U.S. markets throughout 2025, paints a picture of the wholesale cannabis pricing continuing its downward march as markets mature and supply expands — with each market and product category telling a slightly different story.

The Big Picture

Wholesale markets continued to mature in 2025, with many categories experiencing ongoing price compression as supply increased and operators prioritized value. Edibles and ingestibles were a notable exception, with pricing remaining effectively flat year-over-year.

Category by Category

Cartridges experienced the steepest decline, with average prices falling approximately 12% year-over-year, landing at a national average of $13.86 per gram. Pre-Rolls followed closely, dropping more than 10% to $4.66 per gram, while Concentrates fell 7.5% to $9.25 per gram, and Flower posted moderate decreases.

The April 2026 Department of Justice rescheduling order landed with the weight of a decade of advocacy behind it. For an industry that has watched every other legal sector deduct its rent, payroll, and marketing costs while cannabis operators paid taxes on money they never made, the optimism is more than justified. It is earned. The uncertainty, however, is just as real.

A Quick Reminder of Current Law

Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Operators may deduct the cost of goods sold under §471 and nothing else. The result is effective federal tax rates of 60 to 80 percent, and in some cases well beyond, on businesses that are licensed, regulated, and paying state taxes like any other industry. Among the largest publicly traded multi-state operators, contested 280E tax liability now exceeds $1.7 billion collectively.

Why Rescheduling Moves the Needle

The statutory logic is clean. As cannabis tax attorneys have broadly noted, a completed Schedule III reclassification could eliminate 280E by its own terms, potentially improving operator profitability overnight, in some cases dramatically.

What the April Order Actually Does

Here is where the headline optimism requires a reality check. The April 23 order covers two categories: FDA-approved cannabis products and cannabis produced by operators holding a state-issued medical license. That is it (at least for now).